Sharib, J., Liu, A., McIntyre, S., Rhodin, K. E., Kemeny, N. E., Cercek, A., … Lidsky, M. E. (2023). Adjuvant Chemotherapy for Resected Intrahepatic Cholangiocarcinoma Confers No Survival Advantage. In ANNALS OF SURGICAL ONCOLOGY (Vol. 30, pp. S10–S10).

Sharib, Jeremy, Annie Liu, Sarah McIntyre, Kristen E. Rhodin, Nancy E. Kemeny, Andrea Cercek, James J. Harding, et al. “Adjuvant Chemotherapy for Resected Intrahepatic Cholangiocarcinoma Confers No Survival Advantage.” In ANNALS OF SURGICAL ONCOLOGY, 30:S10–S10, 2023.

Sharib J, Liu A, McIntyre S, Rhodin KE, Kemeny NE, Cercek A, et al. Adjuvant Chemotherapy for Resected Intrahepatic Cholangiocarcinoma Confers No Survival Advantage. In: ANNALS OF SURGICAL ONCOLOGY. 2023. p. S10–S10.

Sharib, Jeremy, et al. “Adjuvant Chemotherapy for Resected Intrahepatic Cholangiocarcinoma Confers No Survival Advantage.” ANNALS OF SURGICAL ONCOLOGY, vol. 30, no. SUPPL 1, 2023, pp. S10–S10.

Sharib J, Liu A, McIntyre S, Rhodin KE, Kemeny NE, Cercek A, Harding JJ, Abou-Alfa GK, Soares KC, Wei AC, Drebin J, Kingham TP, D’Angelica MI, Uronis H, Strickler JH, Morse MA, Zani S, Allen PJ, Jarnagin WR, Lidsky ME. Adjuvant Chemotherapy for Resected Intrahepatic Cholangiocarcinoma Confers No Survival Advantage. ANNALS OF SURGICAL ONCOLOGY. 2023. p. S10–S10.